Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The first reported case of a child with two different rare metabolic disorders: Very Long-Chain acyl-CoA dehydrogenase deficiency and encephalomyopathic mitochondrial DNA depletion syndrome 13
Joint Event 12th International Conference on Mental Health and Human Resilience & 9th International Conference on Mental Health and Psychiatry
One of the most common inborn errors in fatty acid β oxidation (FAO) is a very long-chain acyl-coenzyme
A dehydrogenase (VLCAD) deficiency. It is autosomal recessive. The enzyme used in the first phase of
FAO is VLCAD. The enzyme is responsible for βoxidation spiral pathway’s initial step, the dehydrogenation
process of long-chain fatty acyl-CoA. The phenotypes include hypoglycemia, hepatomegaly, cardiomyopathy,
and occasionally abrupt mortality. Most VLCAD deficiencies in newborns are now detected during the neonatal
period due to the development of newborn screening programs. Mitochondrial DNA depletion syndromes
(MTDPS) are one of the rarest metabolic disorders. It is an autosomal recessive disease caused by defects
in genes necessary for the maintenance of mitochondrial DNA (mtDNA). One of these FBXL4 (F-box and
leucine-rich repeat protein 4) variants causes encephalomyopathic mtDNA depletionsyndrome 13 (MTDPS13),
which presents as a failure to thrive, severe global develop-mental delay, hypotonia, early infantile onset of
encephalopathy, and lactic acidosis. We report here the case of a Saudi infant born to consanguineous parents
who presented to us with severe failure to thrive, profound neurodevelopmental delays, and facial dysmorphic
features. Whole-exome sequencing (WES) showed the infants hadMTDPS13. The FBXL4 variant c.1698A > G
p. (Ile566Met) has previously been described as a disease that causes developmental delay and lactic acidosis,
and another variant has also been detected in the patient. The ACADVL variant c.134C > A p. (Ser45) has
previously been described to cause VLCAD deficiency. A comprehensive literature review showed our patient
to be the first case of MTDPS13 and VLCAD reported to date worldwide
Conclusion: This particular infant, the occurrence of these two uncommon metabolic disorders resulted in
quite an unusual clinical presentation. The rise in “double trouble” instances shows that it is worthwhile to look
for a more accurate diagnosis when an already established phenotype is compounded by unusual traits and
difficult diagnosis.
Biography
Maha Alotaibi is a champion of genetic disease in ministry of health. She has plenty of researches in genetic and metabolic disorders and Ad- Hoc Reviewer. She is training and teaching the medical students from different medical collages and residents in Riyadh. She also participates as a speaker in international and local conferences
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals